SR3 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Global Revenue And Market Share GrowthStrong growth across China, APAC, the Americas and EMEA ex-Middle East, alongside reported share gains, supports a durable expansion runway for ICL procedures. Geographic traction can improve operating leverage as scale builds.
High Margins And Conservative Balance SheetVery high gross margins and a debt-free balance sheet provide financial flexibility to fund capacity, innovation and market expansion. Recent cash growth and expected second-half free cash flow could strengthen resilience if profitability improves.
Established ICL Platform And Innovation PipelineA long clinical track record, broad international deployment and an established Collamer platform support surgeon confidence and adoption. Continued EVO Plus and next-generation development may extend the product cycle beyond one core offering.
Bears Say
Weak Cash Conversion And Volatile ProfitabilityDespite the recent quarterly rebound, negative TTM operating and free cash flow and thin net margins show weak conversion from sales to cash. This makes funding growth and sustaining profitability less predictable over the next several quarters.
Capacity Constraints And Tariff ExposureDemand exceeding manufacturing capacity has created backorders, while tariffs on China shipments suppress gross margin until Swiss production reaches full coverage. Capacity expansion and relocation execution remain important to protect growth and margins.
China Concentration And Regional VolatilityHeavy reliance on China makes consolidated performance sensitive to local refractive-market variability and seasonal demand shifts. Currency pressure in Japan and weakness linked to Middle East conflicts add further geographic volatility to reported growth.
Staar Surgical News
SR3 FAQ
What was Staar Surgical’s price range in the past 12 months?
Currently, no data Available
What is Staar Surgical’s market cap?
Staar Surgical’s market cap is CHF989.38M.
When is Staar Surgical’s upcoming earnings report date?
Staar Surgical’s upcoming earnings report date is Nov 04, 2026 which is in 75 days.
How were Staar Surgical’s earnings last quarter?
Staar Surgical released its earnings results on Aug 12, 2026. The company reported CHF0.128 earnings per share for the quarter, missing the consensus estimate of CHF0.177 by -CHF0.049.
Is Staar Surgical overvalued?
According to Wall Street analysts Staar Surgical’s price is currently Undervalued.
Does Staar Surgical pay dividends?
Staar Surgical does not currently pay dividends.
What is Staar Surgical’s EPS estimate?
Staar Surgical’s EPS estimate is 0.04.
How many shares outstanding does Staar Surgical have?
Currently, no data Available
What happened to Staar Surgical’s price movement after its last earnings report?
Staar Surgical reported an EPS of CHF0.128 in its last earnings report, missing expectations of CHF0.177. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Staar Surgical?
Currently, no hedge funds are holding shares in CH:SR3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Staar Surgical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF24.06 (― Upside)
CHF24.06 (― Upside)
Blogger Sentiment
Bullish
CH:SR3 Sentiment 60%
Sector Average 61%
Sector Average 61%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.55%
Trailing 12-Months
Company Description
Staar Surgical
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
SR3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted a strong operational and financial recovery: record first-half revenue, significant YoY top-line growth (Q2 net sales +111%), return to profitability (net income $8.1M; adjusted EBITDA $20M), improved cash balance and strategic progress on product launches (EVO Plus) and ERP deployment. Key risks remain—supply constraints (EVO Plus demand outstripping capacity), tariff-related margin pressure until Swiss manufacturing is fully ramped, regional seasonality and market variability (China seasonality, EMEA/Middle East impacts), and near-term ERP and transition costs. On balance the positive financial turnaround, market share gains in China, and clear roadmap for innovation outweigh the operational headwinds.View all CH:SR3 earnings summaries








